Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients
Authors
Keywords
-
Journal
LEUKEMIA
Volume 28, Issue 12, Pages 2311-2316
Publisher
Springer Nature
Online
2014-07-25
DOI
10.1038/leu.2014.227
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis
- (2014) L. Diomede et al. BLOOD
- Update on treatment of light chain amyloidosis
- (2014) S. Mahmood et al. HAEMATOLOGICA
- Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity
- (2013) Jian Guan et al. BASIC RESEARCH IN CARDIOLOGY
- Systemic light chain amyloidosis: an update for treating physicians
- (2013) G. Merlini et al. BLOOD
- A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
- (2013) A. D. Wechalekar et al. BLOOD
- Light chain amyloidosis: the heart of the problem
- (2013) G. Merlini et al. HAEMATOLOGICA
- Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach
- (2013) G. Palladini et al. HAEMATOLOGICA
- New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
- (2013) E M Ocio et al. LEUKEMIA
- Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
- (2012) J. R. Mikhael et al. BLOOD
- Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
- (2012) C. P. Venner et al. BLOOD
- New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
- (2012) Giovanni Palladini et al. JOURNAL OF CLINICAL ONCOLOGY
- Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
- (2012) Shaji Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
- (2012) H Landau et al. LEUKEMIA
- Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
- (2012) R L Comenzo et al. LEUKEMIA
- Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis
- (2011) Riccardo Caccialanza et al. ANNALS OF HEMATOLOGY
- Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
- (2011) D. E. Reece et al. BLOOD
- Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue
- (2011) F. Brambilla et al. BLOOD
- How to manage primary amyloidosis
- (2011) M A Gertz LEUKEMIA
- Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
- (2011) S. W. Dubrey et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
- Introducing the New Editor ofAmyloid: the Journal of Protein Folding Disorders, Per Westermark, M.D., Ph.D.
- (2010) Martha Skinner et al. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement
- (2010) S. Dietrich et al. BLOOD
- Transplantation vs. conventional-dose therapy for amyloidosis
- (2010) Giovanni Palladini et al. CURRENT OPINION IN ONCOLOGY
- Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
- (2010) Efstathios Kastritis et al. JOURNAL OF CLINICAL ONCOLOGY
- Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients
- (2010) Meghan Rourke et al. LEUKEMIA & LYMPHOMA
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
- (2009) D. E. Reece et al. BLOOD
- Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine
- (2009) G. Palladini et al. CLINICAL CHEMISTRY
- Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
- (2008) A. D. Wechalekar et al. HAEMATOLOGICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now